Our patented Molecular Envelope Technology (MET) platform is being used to grow our Central Nervous System (CNS) disorder pipeline. The current CNS product indications include Post Traumatic Stress Disorder (PES200), and Rare Pediatric Epilepsy (NobrXiol).
MET will significantly improve our drug delivery process characteristics by directly targeting the brain to manage CNS disorder symptoms.
Virpax is collaborating with the Epilepsy Therapy Screening Program (ETSP) to begin preclinical development of NobrXiol for the treatment of pediatric epilepsy. The mission of ETSP is to identify novel agents that may address unmet medical needs in epilepsy.